653 results on '"Röth, Alexander"'
Search Results
152. Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes
153. Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies
154. Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients
155. One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment
156. Porphyria cutanea tarda
157. Cold agglutinine disease
158. Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT
159. Complement‐mediated hemolysis persists year round in patients with cold agglutinin disease.
160. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
161. Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
162. Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy
163. Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)
164. High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
165. Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38+ chronic lymphocytic leukaemia
166. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria
167. Dyskeratosis congenita
168. Seasonal patterns of anemia, hemolytic markers, healthcare resource utilization, and thromboembolic events in cold agglutinin disease
169. A phase 3 study of Ravulizumab (ALXN1210) vs. Eculizumab in adults with paroxysmal nocturnal hemoglobinuria currently treated with Eculizumab : subgroup analysis by transfusion history and demographics
170. Clonal evolution in eltrombopag-resistant aplastic anemia indicated by a novel mutation in transcripts of the thrombopoietin-receptor MPL : a case report
171. Subcutaneous Crovalimab (SKY59) for PNH : COMPOSER long term follow-up
172. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
173. Telomeres in Hematopoietic Stem Cells
174. Telomerase levels control the lifespan of human T lymphocytes
175. Results of a phase 2 study as a rationale for the BELIEVE study, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept in adult patients (Pts) requiring regular RBC transfusions due to β-Thalassemia (β-Thal)
176. Thrombotic storm leading to the diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)
177. Thiotepa-based Autologous hematopoietic stem cell transplantation (ASCT) for CNS or non-CNS lymphoma : first results of a prospective, multicenter, non-interventional study
178. Antithymocyte Globulin (ATG), CSA and eltrombopag followed by autologous stem cell transplantation in a patient with Very Severe Aplastic Anemia (vSAA) and life-threatening pneumonia
179. Sickle Cell Disease (SCD) : A single-centre experience
180. Veno-venous Extracorporal Membrane Oxygenation (VV-ECMO) in a female patient with Sickle Cell Disease (SCD) and Fulminat Acute Chest Syndrome (ACS) : A case report
181. Optimization of dose regimen for ALXN1210, a novel complement C5 inhibitor, in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) : results of 2 phase 1/2 studies
182. Subacute aortic dissection in a patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) on chronic treatment with eculizumab
183. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation
184. Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition
185. Immunosuppressive therapy (IST) in adult patients with acquired aplastic anemia (AA): A single‐center experience over the past 15 years
186. Cold agglutinin disease: current challenges and future prospects
187. Serologic Response to Meningococcal Vaccination in Patients with Cold Agglutinin Disease (CAD) in the New Era of Complement Inhibition
188. A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria
189. The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
190. Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab
191. Seasonal Patterns of Anemia, Hemolytic Markers and Healthcare Resource Utilization Among Patients with Cold Agglutinin Disease in the United States: A Retrospective Analysis
192. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
193. Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy
194. Clinical Profile and Long-Term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis
195. Acral ischemia as a presenting manifestation of essential thrombocythemia
196. Nodular lesions of the scalp and a mediastinal mass in T cell acute lymphoblastic leukemia
197. Paroxysmal nocturnal hemoglobinuria turning Coombs-positive
198. Response to anti-thymocyte globulin (ATG) in patients with Aplastic Anemia (AA) : a single-centre experience over the last 28 years
199. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
200. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.